Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?
Ver/
Fecha
2021
2021
Autor
Chávez-Castillo, Mervin
Ortega, Ángel
Cudris-Torres, Lorena
Duran, Pablo
Rojas, Milagros
Manzano, Alexander
Garrido, Bermary
Salazar, Juan
Silva, Aljadis
Rojas-Gomez, Diana Marcela
De Sanctis, Juan B.
Bermúdez, Valmore
Metadatos
Mostrar el registro completo del ítem
Mostrar el registro completo del ítem
Resumen
Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.
Enlace para referencia:
https://hdl.handle.net/20.500.12442/8636
https://hdl.handle.net/20.500.12442/8636
Enlace DOI:
https:// doi.org/10.3390/ijms221910370
https:// doi.org/10.3390/ijms221910370
Enlace URL externo:
https://www.mdpi.com/1422-0067/22/19/10370/htm
https://www.mdpi.com/1422-0067/22/19/10370/htm